



DOCKET NO: 17311 (BOT)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/648,692
Applicant: Dolly, J. O., *et al.*
Confirmation No.: 6378
Filed: August 25, 2000

Group Art Unit: 1653
Examiner: Bugaisky, G. E.

Docket No.: 17311 (BOT)
Customer No.: 51957
Patent Title: Activatable Recombinant
Neurotoxin

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL WITH SUFFICIENT POSTAGE UNDER 37 C.F.R. §1.8 ON THE DATE INDICATED BELOW IN AN ENVELOPE ADDRESSED TO: MAIL STOP NON-FEE AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Date of Deposit: 6-20-05

Person making Deposit: BONNIE FERGUSON

Signature: Bonnie Ferguson

Date of Signature: 6-20-05

37 C.F.R. §1.133 APPLICANTS' INTERVIEW SUMMARY

June 21, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir,

This two page communication is a summary of the Applicants telephone interview with the Examiner on June 15, 2005.

Pending claims 20-20-33 and 35-37 and proposed amended and new claims submitted by the Applicants were discussed in lieu of WO98/07864, Clifford C. Shone *et al.*, Recombinant Toxin Fragments (Feb. 26, 1998) and US 6,461,617, Clifford C. Shone *et al.*, Recombinant Toxin Fragments (Oct. 8, 2002). The general thrust of the principal argument centered on whether a non-human protease cleavage site could or could not be cleaved by a human protease. The appropriateness of trademark names in a claim was also discussed.

Serial No.: 09/648,692 Activatable Recombinant Neurotoxin
Filed: August 25, 2000

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Dean G. Stathakis", followed by a long horizontal flourish.

Dean G. Stathakis, Ph.D.
Registration No. 54,465
Agent of Record



ALLERGAN

LEGAL DEPARTMENT

2525 Dupont Drive

Irvine, California 92612-1599

Tel: 714/246-6521

Fax: 714/246-4249